Provectus

HIRING · 6 OPEN AI

About

At Provectus, we are obsessed with technologies that impact the future of the whole of humanity. Just imagine: AI for curing eye diseases, ML for making factories safe for workers, preventing pandemic spreading, etc. It’s not about the future, it’s about the products we’ve already developed with ProvectusTeam.

Provectus

About

Updates & Highlights

Provectus Biopharmaceuticals, Inc. Revenue Breakdown – OTC:PVCT

Form 13D/A PROVECTUS BIOPHARMACEUTICALS For: 22 July By Investing.com

Provectus Biopharmaceuticals (PVCT) CEO holds 52.4M shares, 11.61% stake

Recent Openings

All Jobs

Culture & Mission

Benefits & Perks

Health Insurance

Remote Work

Learning Budget

Generous PTO

Competitive Salary

Equity/Stock Options

Tech Stack

Core Values

Innovation

Collaboration

Excellence

Impact

Office Locations

Team

Are you on the team at Provectus?

News & Press

Provectus Biopharmaceuticals, Inc. Revenue Breakdown – OTC:PVCT

Form 13D/A PROVECTUS BIOPHARMACEUTICALS For: 22 July By Investing.com

Provectus Biopharmaceuticals (PVCT) CEO holds 52.4M shares, 11.61% stake

Form 13D/A PROVECTUS BIOPHARMACEUTICALS For: 22 July By Investing.com

Croatian fund Provectus invests in Haelan Healthcare Group

Dentons advises Invenio Partners on the sale of a majority stake in Haelan healthcare to Provectus Capital Partners

Provectus enters Bulgaria with healthcare investment

Croatia's Provectus to buy majority stake in Bulgarian healthcare group from INVENIO

Quotech and Provectus deliver AI-powered underwriting tech to Convex’s new MGA platform

French melanoma study finds the same dose of Provectus RBS can boost and suppress immunity

Provectus Biopharmaceuticals Inc (OTC: PVCT) Share Price, PVCT Stock News, PVCT Share Price & Updates

Form 4 Provectus Biopharmaceuticals Inc For: 2 July By Investing.com

Provectus Converts Directors’ Fees into Series D-1 Equity

Provectus (NASDAQ: PVCT) CEO updates Form 4 to correct Series D-1 preferred holdings

Provectus (PVCT) swaps $542,500 director fees for Series D-1 preferred

Provectus converts directors' accrued fees into Series D-1 Preferred Stock

Provectus (PVCT) president receives grant of Series D-1 convertible preferred stock

Provectus (PVCT) director awarded Series D-1 convertible preferred stock grant

Provectus director granted Series D-1 preferred shares | PVCT Insider Trading

Form 4 Provectus Biopharmaceuticals Inc For: 30 June By Investing.com